experimental drugs
Coverage of experimental drugs in the Nexus archive.
- Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker
Zealand Pharma's stock experienced its two worst days on record as market enthusiasm for one of its experimental drugs waned. Investors are now focusing on amylin-based medicines as a potential growth driver for the company.
- Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy.
New experimental weight-loss drugs are being developed to improve upon existing GLP-1 therapies like Zepbound and Wegovy. These therapies aim to offer better alternatives for patients experiencing nausea or daily pill regimens.
- My son has a terminal disease — why FDA delays are failing families like mine
A mother caring for her son with Duchenne muscular dystrophy criticizes the FDA for regulatory delays in approving experimental drugs, arguing that bureaucratic caution harms terminally ill children. She calls for FDA Commissioner Dr. Martin Makary to address the issue and appoint a successor to Dr. Vinay Prasad who prioritizes patient access over caution.